CN104193660B - 取代的1,3-二苯基丙烷衍生物、它们的制备及用途 - Google Patents

取代的1,3-二苯基丙烷衍生物、它们的制备及用途 Download PDF

Info

Publication number
CN104193660B
CN104193660B CN201410016196.3A CN201410016196A CN104193660B CN 104193660 B CN104193660 B CN 104193660B CN 201410016196 A CN201410016196 A CN 201410016196A CN 104193660 B CN104193660 B CN 104193660B
Authority
CN
China
Prior art keywords
compound
group
phenyl
dimethyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410016196.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104193660A (zh
Inventor
J-F·德洛梅尔
R·汉夫
K·科蒙-贝特朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of CN104193660A publication Critical patent/CN104193660A/zh
Application granted granted Critical
Publication of CN104193660B publication Critical patent/CN104193660B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/45—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms doubly-bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201410016196.3A 2006-06-21 2007-06-21 取代的1,3-二苯基丙烷衍生物、它们的制备及用途 Active CN104193660B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0605540A FR2902789A1 (fr) 2006-06-21 2006-06-21 Derives de 1,3-diphenylpropane substitues, preparations et utilisations
FR0605540 2006-06-21
CN200780030962.XA CN101506138B (zh) 2006-06-21 2007-06-21 取代的1，3-二苯基丙烷衍生物、它们的制备及用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780030962.XA Division CN101506138B (zh) 2006-06-21 2007-06-21 取代的1，3-二苯基丙烷衍生物、它们的制备及用途

Publications (2)

Publication Number Publication Date
CN104193660A CN104193660A (zh) 2014-12-10
CN104193660B true CN104193660B (zh) 2018-10-19

Family

ID=37845179

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410016196.3A Active CN104193660B (zh) 2006-06-21 2007-06-21 取代的1,3-二苯基丙烷衍生物、它们的制备及用途
CN200780030962.XA Active CN101506138B (zh) 2006-06-21 2007-06-21 取代的1，3-二苯基丙烷衍生物、它们的制备及用途
CN2007800310203A Expired - Fee Related CN101506139B (zh) 2006-06-21 2007-06-21 取代的1，3-二苯基丙烷衍生物、它们的制备及用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN200780030962.XA Active CN101506138B (zh) 2006-06-21 2007-06-21 取代的1，3-二苯基丙烷衍生物、它们的制备及用途
CN2007800310203A Expired - Fee Related CN101506139B (zh) 2006-06-21 2007-06-21 取代的1，3-二苯基丙烷衍生物、它们的制备及用途

Country Status (22)

Country Link
US (2) US8188148B2 (https=)
EP (2) EP2046715B1 (https=)
JP (2) JP5350231B2 (https=)
KR (2) KR101416257B1 (https=)
CN (3) CN104193660B (https=)
AU (2) AU2007262939B2 (https=)
BR (1) BRPI0713600B1 (https=)
CA (2) CA2655643C (https=)
CY (2) CY1115082T1 (https=)
DK (2) DK2046716T3 (https=)
EA (1) EA018437B1 (https=)
ES (2) ES2434071T3 (https=)
FR (1) FR2902789A1 (https=)
IL (2) IL196057A (https=)
MX (1) MX2008016239A (https=)
NO (1) NO341866B1 (https=)
NZ (1) NZ573674A (https=)
PL (2) PL2046715T3 (https=)
PT (2) PT2046715E (https=)
SI (2) SI2046715T1 (https=)
WO (2) WO2007147879A1 (https=)
ZA (1) ZA200810709B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902789A1 (fr) * 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
FR2917084B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
EA020849B1 (ru) 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
US9221751B2 (en) * 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
SI2571843T1 (en) 2010-05-17 2018-04-30 Genfit Improved preparation of calcium derivatives
WO2012007365A1 (en) * 2010-07-12 2012-01-19 F. Hoffmann-La Roche Ag 1-hydroxyimino-3-phenyl-propanes
EP2780330B1 (en) * 2011-11-14 2016-01-06 F.Hoffmann-La Roche Ag 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists
SG11201403107TA (en) * 2011-12-28 2014-09-26 Genfit 1,3-diphenylpropane derivatives, preparations and uses thereof
EP3416629A4 (en) * 2016-02-16 2019-08-07 CoNCERT Pharmaceuticals, Inc. DEUTERATED GFT-505
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
IT201600098338A1 (it) * 2016-09-30 2018-03-30 Univ Degli Studi Padova Composti 1-fenilpropanone e loro impiego
RU186145U1 (ru) * 2018-08-08 2019-01-11 Общество с ограниченной ответственностью "Научно-производственное объединение "Центротех" (ООО "НПО "Центротех") Каркас виброрамы вибросита
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20220140762A (ko) 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN114901641B (zh) * 2020-02-28 2025-06-17 四川科伦博泰生物医药股份有限公司 芳香族化合物及其药物组合物和用途
AU2021275381A1 (en) 2020-05-18 2022-11-24 Genfit Elafibranor for the treatment of primary sclerosing cholangitis
WO2022043367A1 (en) 2020-08-26 2022-03-03 Genfit Compositions and methods for the treatment of primary biliary cholangitis
EP4337184A1 (en) 2021-05-11 2024-03-20 Genfit Ppar-agonists for use in the treatment of liver failure
WO2022238451A1 (en) 2021-05-11 2022-11-17 Genfit Elafibranor and 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl] phenoxy]-2-methylpropanoic acid analog as ppar-agonists for use in the treatment of sepsis
TW202527918A (zh) 2023-10-13 2025-07-16 法商Ｇｅｎｆｉｔ公司 原發性膽汁性膽管炎之治療方法
WO2025088067A1 (en) 2023-10-25 2025-05-01 Genfit Elafibranor for the treatment of primary biliary cholangitis
WO2025215081A1 (en) 2024-04-09 2025-10-16 Genfit Elafibranor for use for long-term treatment of primary biliary cholangitis
WO2026047132A1 (en) 2024-08-29 2026-03-05 Genfit Treatment of advanced primary biliary cholangitis
CN119490528A (zh) * 2025-01-17 2025-02-21 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种HSP90α选择性抑制剂及其合成方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87104753A (zh) * 1986-07-11 1988-06-15 奇诺英药物化学工厂有限公司 制备新的联二苯正丙胺衍生物及其盐的方法
DE4121849A1 (de) * 1991-07-02 1993-01-14 Rhone Poulenc Rorer Gmbh (4-((omega)-arylalkyl)-phenyl)alkansaeuren, ihre salze und/oder ihre derivate
CA2169187A1 (en) * 1993-08-14 1995-02-23 Ernst-Christian Witte Use of phenols and phenol derivatives as pharmaceutical agents with a fibrinogen-lowering action
CN1373745A (zh) * 1999-07-16 2002-10-09 格吕伦塔尔有限公司 3－氨基－2－苄基－1－苯基丙烷衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070C3 (de) 1971-10-01 1978-03-23 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel
NZ515086A (en) * 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
AU2004283147A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
FR2902789A1 (fr) 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN87104753A (zh) * 1986-07-11 1988-06-15 奇诺英药物化学工厂有限公司 制备新的联二苯正丙胺衍生物及其盐的方法
DE4121849A1 (de) * 1991-07-02 1993-01-14 Rhone Poulenc Rorer Gmbh (4-((omega)-arylalkyl)-phenyl)alkansaeuren, ihre salze und/oder ihre derivate
CA2169187A1 (en) * 1993-08-14 1995-02-23 Ernst-Christian Witte Use of phenols and phenol derivatives as pharmaceutical agents with a fibrinogen-lowering action
CN1373745A (zh) * 1999-07-16 2002-10-09 格吕伦塔尔有限公司 3－氨基－2－苄基－1－苯基丙烷衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and Hypolipidemic Activity of %-SubstitutedI sobutyric Acid Derivatives;Shin-ichi Morishita等;《J.Med.Chem.》;19881231;第31卷;第1206页table1 *
w-[(w-Arylalkyl)aryl]alkanoic Acids: A New Class of Specific LTA4 Hydrolase Inhibitors;Richard Labaudinikre等;《J.Med.Chem》;19921231;第35卷;全文 *

Also Published As

Publication number Publication date
PT2046715E (pt) 2014-05-26
BRPI0713600B1 (pt) 2021-07-13
EP2046716B1 (fr) 2013-08-14
EA200900044A1 (ru) 2009-06-30
ZA200810709B (en) 2009-12-30
FR2902789A1 (fr) 2007-12-28
JP2009541269A (ja) 2009-11-26
AU2007262939A1 (en) 2007-12-27
AU2007262938A1 (en) 2007-12-27
US8188148B2 (en) 2012-05-29
JP2009541270A (ja) 2009-11-26
CA2655643A1 (fr) 2007-12-27
ES2466268T3 (es) 2014-06-09
US20110136888A1 (en) 2011-06-09
DK2046715T3 (da) 2014-06-02
US20100286276A1 (en) 2010-11-11
NZ573674A (en) 2012-02-24
SI2046715T1 (sl) 2014-08-29
CN101506138A (zh) 2009-08-12
CN101506139A (zh) 2009-08-12
NO20085338L (no) 2009-03-23
PT2046716E (pt) 2013-11-11
KR20090035535A (ko) 2009-04-09
JP5350231B2 (ja) 2013-11-27
JP5350230B2 (ja) 2013-11-27
CN104193660A (zh) 2014-12-10
EP2046716A1 (fr) 2009-04-15
EP2046715B1 (fr) 2014-04-16
AU2007262939B2 (en) 2012-04-05
SI2046716T1 (sl) 2014-02-28
WO2007147879A1 (fr) 2007-12-27
WO2007147880A1 (fr) 2007-12-27
CA2655643C (fr) 2016-03-22
NO341866B1 (no) 2018-02-12
CN101506138B (zh) 2014-02-19
KR20090059105A (ko) 2009-06-10
KR101416262B1 (ko) 2014-07-16
IL196057A (en) 2012-07-31
MX2008016239A (es) 2009-02-25
DK2046716T3 (da) 2013-11-04
CN101506139B (zh) 2012-10-10
CY1115414T1 (el) 2017-01-04
IL196057A0 (en) 2009-09-01
IL196071A0 (en) 2009-09-01
EA018437B1 (ru) 2013-08-30
CA2655744C (fr) 2016-03-22
DK2046715T5 (da) 2014-07-28
EP2046715A1 (fr) 2009-04-15
KR101416257B1 (ko) 2014-07-16
BRPI0713600A2 (pt) 2012-11-06
CA2655744A1 (fr) 2007-12-27
ES2434071T3 (es) 2013-12-13
PL2046716T3 (pl) 2014-03-31
US8258182B2 (en) 2012-09-04
AU2007262938B2 (en) 2012-04-05
PL2046715T3 (pl) 2014-07-31
CY1115082T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
CN104193660B (zh) 取代的1,3-二苯基丙烷衍生物、它们的制备及用途
CN101969773B (zh) 用于降低尿酸的化合物和方法
WO2008087365A2 (fr) Derives de 1,3-diphenylpropane substitues, preparations et utilisations
JP4435418B2 (ja) 新規レチノイドおよびその使用法
CN100393309C (zh) 具有降低血清葡萄糖和降低血清脂质活性的α-苯硫基羧酸和α-苯氧基羧酸的用途
AU2012360796B2 (en) 1,3-diphenylpropane derivatives, preparations and uses thereof
JP5097043B2 (ja) イオウ含有化合物、その調製方法および薬学的使用
JP2005053780A (ja) 核内レセプタースーパーファミリーの新規リガンド、その製法及び用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant